Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-22 16:42 CEST (UTC+2h)

Product-specific advice (Benserazide+levo­dopa) [Design Issues]

posted by Mikalai - Belarus, 2018-01-09 14:37  - Posting: # 18153
Views: 845

Dear all,
We plan to conduct the bioequivalence study of levodopa and benserazide. We approached several experts to write a protocol of the study. However, they informed us that there is a substantial lack of information on the pharmacokinetics of benserazide to finalize the protocol. We probably cannot ask our competent authority for advice because they may not have necessary information. Thus, we have several important questions in relation to benserazide.

Should we quantify in serum only Benserazide or its metabolite, or both?

What are criteria for bioequivalence (bioequivalence should be established only on the levodopa data or on the data of both components? bioequivalence acceptance criteria?)?

What is the best design for the study?

Any suggestions where and from whom we can obtain reliable advice on the above-mentioned issues will be appreciated.
Sincerely,
Mikalai


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,191 registered users;
online 12 (1 registered, 11 guests [including 11 identified bots]).

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed